BRAIN Biotech AG (HAM:BNN) Beta: 1.1247 (As of Jun. 26, 2026)


HAM:BNN BRAIN Biotech AG HAM:BNN
65 GF Score
Price €2.82
GF Value €2.51
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG Beta?

BRAIN Biotech AG HAM:BNN 65 Beta is 1.1247 as of Jun. 26, 2026. GuruFocus rates HAM:BNN with a GF Score™ of 65/100 and a GF Value™ of €2.51 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-26), BRAIN Biotech AG's Beta is 1.1247.


BRAIN Biotech AG  (HAM:BNN) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


BRAIN Biotech AG Beta Related Terms


BRAIN Biotech AG Beta Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG Beta Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.43 1.29 1.10 1.44 1.65

BRAIN Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.56 1.74 1.65 -1.22 1.13

HAM:BNN vs LIN, SHW, ECL: Beta Comparison

For the Specialty Chemicals subindustry, BRAIN Biotech AG's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG Beta vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's Beta distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's Beta falls into.


HAM:BNN
65GF Score
BRAIN Biotech AG HAM:BNN
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRAIN Biotech AG Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.1247 mean?
BRAIN Biotech AG (HAM:BNN) has a Beta of 1.1247 as of Jun. 26, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BRAIN Biotech AG and its competitors.
Is BRAIN Biotech AG's Beta too high?
BRAIN Biotech AG's current Beta is 1.1247. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's Beta compare to LIN and SHW?
BRAIN Biotech AG's Beta of 1.1247 can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Chemicals company?
A good Beta depends on the Chemicals industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current Beta is 1.1247. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Modestly Overvalued. The stock's GF Value™ is €2.51, compared to a current price of €2.82 — trading 12.4% above its estimated fair value. The current Beta is 1.1247. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current Beta is 1.1247 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.82 is trading 12.4% above its estimated GF Value™ of €2.51. GuruFocus considers BRAIN Biotech AG to be Modestly Overvalued.

Key valuation signals for HAM:BNN:

  • Beta: 1.1247
  • GF Value™: €2.51 vs. price of €2.82 (12.4% above fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BRAIN Biotech AG Business Description

Other Exchanges 0RFI:UKBNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score

Get the complete analysis for HAM:BNN

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.82
Price
€2.51
GF Value